European Leukemia Trial Registry
Trial: AML APL-Arsen

More Details
Scientific Title phase IV study with arsenic-trioxide to evaluate efficacy and toxicity as well as influence of kinetics of minimal residual disease in first or high-grade hematological or molecular relapse of acute promyelocytic leukemia (APL) and missing molecular remission after primary therapy
Short Title AML APL-Arsen
Trialgroup NN
Type of Trial multicentric
Disease
Age >= 18 years
Status Closed
Start of Recruitment 30.05.2005
Leader Lengfelder, Prof. Dr. med., Eva
Contactperson

Study Physician
Gnad, Dr. med., Ulrike
Tel: +49 (0)621 383 4110
Fax: +49 (0)621 383 4201
Email: ulrike.gnad@med3.ma.uni-heidelberg.de

Study Physician
Saußele, Prof. Dr. med., Susanne
Tel: +49 (0)621 383-6966
Fax: +49 (0)621 383-4201
Email: susanne.saussele@medma.uni-heidelberg.de

Biometrics
Köpcke, Prof. Dr. med., W.
Tel: +49 (0)251 83 - 5 52 61
Email: kopcke@uni-muenster.de

Centre of Trial Medizinische Fakultät Mannheim der Universität Heidelberg
Shortprotocol Shortprotocol
Diagnostics

Molecular biology
Molekulargenetisches Labor der III Med.Klinik, Universitätsmedizin Mannheim
MLL Münchner Leukämielabor GmbH
Labor für Spezielle Hämatologie und Immunphänotypisierung, Universitätsklinikum Münster

Morphology
MLL Münchner Leukämielabor GmbH

Cytogenetics
MLL Münchner Leukämielabor GmbH

created 03.07.2006 Anja Hellenbrecht
changed 25.06.2009 Roswitha Kotthoff
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org